Navigation Links
Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma

tion about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercial
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:10/10/2008)..., Oct. 10 /- Boston Scienti...schedule of the Company,s major,events and press a...tion,s,(CRF) twentieth annual Transcatheter Cardio...which runs from October 12 to 17 in Washington, D....ange of safety and,efficacy data on its TAXUS(R) E...
(Date:10/9/2008)...s for Increased Sales and Marketing Efforts to Acc...ip(R) System, MENLO PARK, Calif., Oct. 9 /PRNewsw...t of devices for the percutaneous repair of cardia...cutive team with the appointment of,Sean Cleary as...eting and,Chris Richardson, as vice president of s...
(Date:10/8/2008)...a., Oct. 8 /PRNewswire-USNewswire/ -- The facts ar... from HIV/AIDS in,sub-Saharan Africa. More than 35...frica have already died of AIDS. The Foundation fo...ure the dying and their families,find compassion a...,s,innovative partnering initiative links African ...
(Date:10/8/2008)...ab Program to be Discontinued and Headcount to be ...its Portfolio Review; Zanolimumab Program to be D... of Employees, COPE... A/S (OMX: GEN),announced today that it is discont...In addition, as a result of a portfolio review and...
Breaking Medicine Technology:Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 2Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 3Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 4Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 6Evalve Expands Executive Leadership Team 2Evalve Expands Executive Leadership Team 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4The 7 Key Questions About the Schwarzenegger Nunez Health Care Compromise 620 1The 7 Key Questions About the Schwarzenegger Nunez Health Care Compromise 620 2The 7 Key Questions About the Schwarzenegger Nunez Health Care Compromise 620 3The 7 Key Questions About the Schwarzenegger Nunez Health Care Compromise 620 4The 7 Key Questions About the Schwarzenegger Nunez Health Care Compromise 620 5The 7 Key Questions About the Schwarzenegger Nunez Health Care Compromise 620 6New knock out gene model provides molecular clues to breast cancer 615 1New knock out gene model provides molecular clues to breast cancer 615 2New knock out gene model provides molecular clues to breast cancer 615 3Martek Announces Third Quarter 2007 Financial Results 613 1Martek Announces Third Quarter 2007 Financial Results 613 2Martek Announces Third Quarter 2007 Financial Results 613 3Martek Announces Third Quarter 2007 Financial Results 613 4Martek Announces Third Quarter 2007 Financial Results 613 5Martek Announces Third Quarter 2007 Financial Results 613 6Martek Announces Third Quarter 2007 Financial Results 613 7Martek Announces Third Quarter 2007 Financial Results 613 8Martek Announces Third Quarter 2007 Financial Results 613 9Martek Announces Third Quarter 2007 Financial Results 613 10Martek Announces Third Quarter 2007 Financial Results 613 11Martek Announces Third Quarter 2007 Financial Results 613 12IRIDEX Announces Closing of 245 0 Million Private Placement 608 1IRIDEX Announces Closing of 245 0 Million Private Placement 608 2IRIDEX Announces Closing of 245 0 Million Private Placement 608 3IRIDEX Announces Closing of 245 0 Million Private Placement 608 4
...akthrough Will Aid in Developing Therapies to Prev...RYVILLE, Calif., May 10, 2007 /PRNewswire/ -- Kine...lopment company, announced,today the first method ...es in animals through the pathway known as reverse...n mechanism by which excess,cholesterol can be rem...
...POLIS, France, May 11, 2007 /PRNewswire-FirstCall/...pdate on the phase 2a,study for NCX 1000, which is... Pharma Inc. A preliminary analysis of 11 patient...tension confirmed,the safety profile of NCX 1000 b...pport the continuation of this clinical trial. As ...
Other Medicine Technology:KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 2KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 3NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 2NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 3
(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
...000 worth of unapproved dietary supplements in the...e Food and Drug Administration (FDA) agency had re...age Nutraceuticals L.L.C distributed the capsules....at the seized capsules, which are supposedly in vi...
...reast cancer cases in American women appears to ha.../ that a turning point may have reached in the nat...e latest federal data it was found that after a st...cer rate stopped rising in 2001 and may have start...
...ly poetic way to describe a disease that is the fu...s father’s life and, Galvin always knew, threatene...’s sitting out on the horizon that you know one da...ays Galvin, 37. “It’s something I’ve thought about...
...d of the conjoined twins from Wisconsin has been c...ork remains ahead of them.// The lead surgeon, Ro... optimistic about the preservation of neurological...ave decided not to separate the twins' shared tail...
Other Medicine News:Health News:Plateau Reached in the Battle against Breast Cancer 2Health News:Plateau Reached in the Battle against Breast Cancer 3Health News:Deadly Lung Disease Sends Patients on ‘Quest for Breath 2Health News:Deadly Lung Disease Sends Patients on ‘Quest for Breath 3Health News:Separation of Spinal Cord of Conjoined Twins Completed Successfully 2
Gentamicin Reagent Solution (10 mg/ml) liquid
LB Agar plates with 0.1mM EDTA.
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride.
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride.
Medicine Products: